Ampliphi Biosciences (NYSE American: APHB) is a clinical-stage biotechnology company dedicated to developing novel anti-infective therapies to combat drug-resistant bacterial pathogens. Using a proprietary platform of engineered bacteriophage-derived proteins and lysins, Ampliphi focuses on designing targeted treatments that selectively eradicate antibiotic-resistant organisms while sparing healthy microbiota. The company’s pipeline includes lead candidates such as AP-PA02 for carbapenem-resistant Acinetobacter baumannii and AP-GA01 for multidrug-resistant Gram-negative infections, each optimized for stability and systemic delivery.
Ampliphi’s research and development efforts center on a deep library of phage-based enzymes capable of degrading bacterial cell walls and overcoming traditional resistance mechanisms. In preclinical models, these candidates have demonstrated rapid bactericidal activity and efficacy in hard-to-treat infections, including ventilator-associated bacterial pneumonia and complicated urinary tract infections. The company also explores combination approaches with existing antibiotics to restore or enhance their effectiveness against resistant strains.
Founded in 2018 as a spin-out from academic phage research, Ampliphi has grown its footprint across North America and Europe. The company is headquartered in Kansas City, Missouri, with additional research facilities and strategic partnerships in the United Kingdom and Australia. Over the past several years, Ampliphi has advanced multiple candidates into regulatory discussions with the U.S. Food and Drug Administration and European Medicines Agency, positioning itself as a potential leader in next-generation anti-infective development.
Ampliphi is led by President and Chief Executive Officer Daniel Vittor, Ph.D., who brings more than two decades of experience in infectious disease drug development. The executive team includes seasoned professionals in regulatory affairs, clinical operations and pharmaceutical manufacturing, supported by a board of directors with deep expertise in biotechnology and life sciences investment. Together, they aim to address the urgent global need for new therapies against antibiotic-resistant infections.
AI Generated. May Contain Errors.
